The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive factors of bevacizumab efficacy in relapsed glioblastoma patients.
Patrizia Farina
No relevant relationships to disclose
Marianne Labussiere
No relevant relationships to disclose
Giuseppe Lombardi
No relevant relationships to disclose
Anna Luisa Di Stefano
No relevant relationships to disclose
Jaime Gallego
No relevant relationships to disclose
Caroline Cheneau
No relevant relationships to disclose
Vittorina Zagonel
No relevant relationships to disclose
Marc Sanson
No relevant relationships to disclose